the drug was created by tanox under the name tnx 650 and a phase i clinical trial for refractory hodgkin s lymphoma had been performed when genentech acquired tanox in 2007 it has successfully completed a phase ii clinical trial for the treatment of asthma lebrikizumab blocks interleukin 13 il 13 a cytokine cell signalling protein that is produced by a type of white blood cell called th2 cells il 13 is thought to induce the expression of another signalling protein periostin by epithelial cells of the bronchi periostin in turn seems to partake in a number of asthma related problems such as bronchial hyperresponsiveness inflammation and activation and proliferation of airway fibroblasts which are involved in airway remodelling this theory is supported by the fact that patients with high periostin levels responded significantly better to lebrikizumab in the phase ii study the forced expiratory volume in 1 second fev1 was 8 2 higher than under placebo in this group measured from the respective baselines while low periostin patients had 1 6 higher fev1 and the average value for all patients was 5 5 the fev1 increase in low periostin patients was not statistically significant in the study musculoskeletal side